The combination of PCSK9 inhibitors and moderate statin therapy effectively stabilizes intracranial atherosclerotic plaques in patients with intracranial atherosclerotic stenosis (ICAS). The gene discussed is PCSK9; the disease is familial isolated congenital asplenia.